Royalty Pharma (RPRX)
Royalty Pharma on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
12.9M
Short interest
settlement 2026-09-30
4.4
Days to cover
+1.2 days vs prior
33.9%
Short share of volume
2026-10-09
19,550
Fails to deliver
settlement 2026-09-03
Wed 4 Nov
Next earnings
estimated date
-$13.0M
Insider flow, 90 days
0 buys, 7 sells
As of 2026-10-09.
Short interest
FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in RPRX is 12,885,147 shares, up 981,431 shares over the last month. Over the last 48 readings it ranged from 10,667,818 shares (31 July 2026) to 29,032,462 shares (13 June 2025). At the reported average volume of 2.9M shares a day that is 4.4 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/rprx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 12,885,147 | +10.6% | 2,901,553 | 4.44 |
| 2026-09-15 | 11,647,565 | -2.1% | 3,588,237 | 3.25 |
| 2026-08-31 | 11,903,716 | +2.6% | 2,359,488 | 5.05 |
| 2026-08-14 | 11,606,728 | +8.8% | 3,076,318 | 3.77 |
| 2026-07-31 | 10,667,818 | -12.1% | 2,620,765 | 4.07 |
| 2026-07-15 | 12,134,646 | -2.5% | 2,734,023 | 4.44 |
| 2026-06-30 | 12,443,449 | +11.8% | 4,175,279 | 2.98 |
| 2026-06-15 | 11,133,208 | -3.9% | 3,667,098 | 3.04 |
| 2026-05-29 | 11,588,307 | -8.6% | 4,694,064 | 2.47 |
| 2026-05-15 | 12,683,834 | -8.2% | 3,822,354 | 3.32 |
| 2026-04-30 | 13,816,927 | +15.0% | 3,130,697 | 4.41 |
| 2026-04-15 | 12,011,065 | +4.3% | 2,757,214 | 4.36 |
| 2026-03-31 | 11,520,329 | -0.5% | 3,485,136 | 3.31 |
| 2026-03-13 | 11,579,085 | -4.8% | 3,369,561 | 3.44 |
| 2026-02-27 | 12,161,157 | -9.5% | 2,845,619 | 4.27 |
| 2026-02-13 | 13,443,797 | -49.2% | 4,434,841 | 3.03 |
| 2026-01-30 | 26,462,455 | -3.8% | 3,673,067 | 7.20 |
| 2026-01-15 | 27,513,663 | -4.5% | 3,953,531 | 6.96 |
| 2025-12-31 | 28,800,189 | +3.9% | 3,100,616 | 9.29 |
| 2025-12-15 | 27,721,192 | +13.9% | 5,083,212 | 5.45 |
| 2025-11-28 | 24,331,177 | +1.3% | 3,755,485 | 6.48 |
| 2025-11-14 | 24,029,541 | +69.3% | 5,354,117 | 4.49 |
| 2025-10-31 | 14,193,421 | +4.5% | 2,307,997 | 6.15 |
| 2025-10-15 | 13,575,761 | +5.5% | 2,268,707 | 5.98 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 9 October 2026, the short share of RPRX volume is 33.9%, down 14.8 points over the last five sessions. Over the last 30 readings it ranged from 29.3% (30 September 2026) to 73.3% (31 August 2026). The latest reading is 12.4 points below the 30-session average of 46.3%, on 1.0M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-09 | 340K | 1.0M | 33.9% | 0 |
| 2026-10-08 | 334K | 1.0M | 32.5% | 335 |
| 2026-10-07 | 391K | 1.2M | 33.1% | 35 |
| 2026-10-06 | 357K | 1.0M | 34.2% | 0 |
| 2026-10-05 | 682K | 1.9M | 36.9% | 200 |
| 2026-10-02 | 460K | 944K | 48.7% | 226 |
| 2026-10-01 | 567K | 1.1M | 50.7% | 2,373 |
| 2026-09-30 | 534K | 1.8M | 29.3% | 2,114 |
| 2026-09-29 | 541K | 1.1M | 47.7% | 408 |
| 2026-09-28 | 336K | 728K | 46.2% | 482 |
| 2026-09-25 | 305K | 646K | 47.2% | 0 |
| 2026-09-24 | 299K | 694K | 43.1% | 0 |
| 2026-09-23 | 430K | 992K | 43.4% | 21 |
| 2026-09-22 | 462K | 812K | 56.9% | 13,103 |
| 2026-09-21 | 527K | 1.4M | 39.0% | 0 |
| 2026-09-18 | 313K | 756K | 41.4% | 0 |
| 2026-09-17 | 399K | 739K | 53.9% | 0 |
| 2026-09-16 | 391K | 714K | 54.7% | 2,039 |
| 2026-09-15 | 394K | 1.1M | 35.4% | 2,467 |
| 2026-09-14 | 408K | 1.2M | 32.9% | 1,411 |
| 2026-09-11 | 467K | 1.1M | 41.2% | 0 |
| 2026-09-10 | 627K | 1.3M | 49.0% | 200 |
| 2026-09-09 | 755K | 1.7M | 45.2% | 221 |
| 2026-09-08 | 1.6M | 3.9M | 42.1% | 10,875 |
| 2026-09-04 | 805K | 1.3M | 61.5% | 335 |
| 2026-09-03 | 652K | 1.1M | 56.8% | 1 |
| 2026-09-02 | 685K | 1.3M | 51.1% | 4 |
| 2026-09-01 | 532K | 865K | 61.5% | 179 |
| 2026-08-31 | 857K | 1.2M | 73.3% | 94 |
| 2026-08-28 | 480K | 713K | 67.2% | 3 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 3 September 2026, the fails-to-deliver balance in RPRX is 19,550 shares, up 18,467 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (21 August 2026) to 5,715,736 shares (29 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-03 | 19,550 | $63.11 | $1.2M |
| 2026-09-01 | 1,083 | $61.41 | $67K |
| 2026-08-31 | 37,787 | $60.85 | $2.3M |
| 2026-08-26 | 48,494 | $62.07 | $3.0M |
| 2026-08-21 | 2 | $60.58 | $121 |
| 2026-08-03 | 254 | $58.43 | $15K |
| 2026-07-28 | 1,565 | $58.73 | $92K |
| 2026-07-02 | 3 | $55.78 | $167 |
| 2026-06-29 | 5,715,736 | $56.23 | $321.4M |
| 2026-06-24 | 288 | $55.35 | $16K |
| 2026-06-15 | 2,223 | $54.87 | $122K |
| 2026-06-11 | 20 | $54.52 | $1K |
| 2026-06-01 | 335 | $55.76 | $19K |
| 2026-05-29 | 5,666 | $54.48 | $309K |
| 2026-05-26 | 1,786 | $54.50 | $97K |
| 2026-04-22 | 3 | $49.48 | $148 |
| 2026-04-17 | 3,415 | $48.48 | $166K |
| 2026-04-16 | 728 | $48.70 | $35K |
| 2026-04-08 | 3 | $46.87 | $141 |
| 2026-03-09 | 124 | $45.41 | $6K |
| 2026-02-27 | 1,232 | $45.36 | $56K |
| 2026-02-25 | 185,721 | $45.40 | $8.4M |
| 2026-02-20 | 8 | $45.11 | $361 |
| 2026-02-03 | 290 | $42.36 | $12K |
| 2026-01-26 | 21 | $40.40 | $848 |
| 2025-12-26 | 58,764 | $39.25 | $2.3M |
| 2025-11-26 | 430,863 | $39.54 | $17.0M |
| 2025-11-14 | 2,823 | $39.73 | $112K |
| 2025-11-12 | 43,644 | $38.96 | $1.7M |
| 2025-11-10 | 23,476 | $38.56 | $905K |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONInsiders at RPRX reported 7 open-market sells worth $13.0M in the last 90 days and no open-market buys. Latest filing: Urist Marshall (EVP, Research & Investments) on 2026-10-05.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-05 | Urist Marshall | EVP, Research & Investments | Sell | 4K | $57.10 | $236K | 0 |
| 2026-09-30 | Bassler Bonnie L | Director | Grant | 642 | $58.41 | $37K | 80K |
| 2026-09-28 | Urist Marshall | EVP, Research & Investments | Sell | 4K | $57.88 | $239K | 4K |
| 2026-09-22 | Hite Christopher | EVP & Chairman, Partnering | Sell | 4K | $58.93 | $231K | 270K |
| 2026-09-22 | Hite Christopher | EVP & Chairman, Partnering | Sell | 96K | $58.51 | $5.6M | 274K |
| 2026-08-19 | Hite Christopher | EVP & Chairman, Partnering | Gift | 17K | $0.00 | $0 | 23K |
| 2026-08-18 | Hite Christopher | EVP & Chairman, Partnering | Sell | 100K | $59.97 | $6.0M | 370K |
| 2026-08-13 | Coyne Terrance P. | EVP & CFO | Sell | 2K | $59.14 | $105K | 0 |
| 2026-08-13 | Coyne Terrance P. | EVP & CFO | Sell | 9K | $58.59 | $541K | 2K |
| 2026-08-05 | Urist Marshall | EVP, Research & Investments | Grant | 8K | $0.00 | $0 | 8K |
| 2026-08-05 | Legorreta Pablo G. | CEO, Chairman of the Board | Grant | 65K | $0.00 | $0 | 1.3M |
| 2026-08-05 | Hite Christopher | EVP & Chairman, Partnering | Grant | 11K | $0.00 | $0 | 470K |
| 2026-08-05 | Coyne Terrance P. | EVP & CFO | Grant | 11K | $0.00 | $0 | 11K |
| 2026-07-01 | Urist Marshall | EVP, Research & Investments | Sell | 9K | $55.88 | $508K | 0 |
| 2026-06-30 | Hite Christopher | EVP & Chairman, Partnering | Sell | 600 | $57.09 | $34K | 40K |
| 2026-06-30 | Hite Christopher | EVP & Chairman, Partnering | Sell | 29K | $56.44 | $1.7M | 41K |
| 2026-06-30 | Hite Christopher | EVP & Chairman, Partnering | Sell | 3K | $57.10 | $146K | 459K |
| 2026-06-30 | Hite Christopher | EVP & Chairman, Partnering | Sell | 97K | $56.50 | $5.5M | 462K |
| 2026-06-30 | Bassler Bonnie L | Director | Grant | 689 | $54.40 | $37K | 79K |
| 2026-06-24 | Urist Marshall | EVP, Research & Investments | Sell | 9K | $55.18 | $502K | 9K |
| 2026-06-23 | Hite Christopher | EVP & Chairman, Partnering | Sell | 32K | $54.11 | $1.8M | 677K |
| 2026-06-23 | Hite Christopher | EVP & Chairman, Partnering | Sell | 118K | $54.47 | $6.4M | 559K |
| 2026-06-05 | WEATHERMAN ELIZABETH H | Director | Grant | 5K | $0.00 | $0 | 13K |
| 2026-06-05 | Norden Gregory | Director | Grant | 5K | $0.00 | $0 | 196K |
| 2026-06-05 | LOVE TED W | Director | Grant | 5K | $0.00 | $0 | 58K |
| 2026-06-05 | Ho Carole | Director | Grant | 5K | $0.00 | $0 | 5K |
| 2026-06-05 | HODGSON DAVID C | Director | Grant | 5K | $0.00 | $0 | 38K |
| 2026-06-05 | Engelbert Catherine M. | Director | Grant | 5K | $0.00 | $0 | 56K |
| 2026-06-05 | Coric Vlad | Director | Grant | 5K | $0.00 | $0 | 15K |
| 2026-06-05 | Bassler Bonnie L | Director | Grant | 5K | $0.00 | $0 | 78K |
| 2026-05-26 | Coyne Terrance P. | EVP & CFO | Sell | 64K | $53.98 | $3.5M | 0 |
| 2026-05-20 | Urist Marshall | EVP, Research & Investments | Sell | 14K | $52.75 | $722K | 18K |
| 2026-05-14 | Urist Marshall | EVP, Research & Investments | Sell | 14K | $53.06 | $726K | 32K |
| 2026-05-14 | Norden Gregory | Director | Sell | 3K | $53.00 | $161K | 192K |
| 2026-05-06 | Urist Marshall | EVP, Research & Investments | Grant | 18K | $0.00 | $0 | 46K |
| 2026-05-06 | Legorreta Pablo G. | CEO, Chairman of the Board | Grant | 144K | $0.00 | $0 | 1.2M |
| 2026-05-06 | Hite Christopher | EVP & Vice Chairman | Grant | 24K | $0.00 | $0 | 709K |
| 2026-05-06 | Coyne Terrance P. | EVP & CFO | Grant | 24K | $0.00 | $0 | 64K |
| 2026-04-28 | Coyne Terrance P. | EVP & CFO | Sell | 2K | $49.78 | $93K | 40K |
| 2026-04-28 | Coyne Terrance P. | EVP & CFO | Sell | 33K | $49.78 | $1.6M | 0 |
| 2026-04-01 | Coyne Terrance P. | EVP & CFO | Sell | 33K | $48.33 | $1.6M | 33K |
| 2026-04-01 | Coyne Terrance P. | EVP & CFO | Sell | 2K | $48.33 | $91K | 42K |
| 2026-03-31 | Bassler Bonnie L | Director | Grant | 815 | $45.98 | $37K | 74K |
| 2026-03-23 | Coyne Terrance P. | EVP & CFO | Sell | 2K | $45.53 | $85K | 44K |
| 2026-03-23 | Coyne Terrance P. | EVP & CFO | Sell | 33K | $45.53 | $1.5M | 66K |
| 2026-03-02 | Coyne Terrance P. | EVP & CFO | Sell | 583 | $47.01 | $27K | 46K |
| 2026-03-02 | Coyne Terrance P. | EVP & CFO | Sell | 1K | $46.67 | $60K | 46K |
| 2026-03-02 | Coyne Terrance P. | EVP & CFO | Sell | 10K | $47.01 | $490K | 99K |
| 2026-03-02 | Coyne Terrance P. | EVP & CFO | Sell | 22K | $46.67 | $1.0M | 109K |
| 2026-02-23 | Coyne Terrance P. | EVP & CFO | Sell | 2K | $45.32 | $85K | 48K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON10 Form 144 notices on file for RPRX worth $11.6M at the prices reported; 2 in the last 90 days worth $474K. Latest: Urist Marshall filed on 2026-10-05 to sell 4,126 shares ($236K) from 2026-10-05.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-05 | Urist MarshallOfficer | 4K | $236K | 0.001% | 2026-10-05 | Merrill Lynch |
| 2026-09-28 | Urist MarshallOfficer | 4K | $239K | 0.001% | 2026-09-28 | Merrill Lynch |
| 2026-07-01 | Urist MarshallOfficer | 9K | $508K | 0.002% | 2026-07-01 | Merrill Lynch |
| 2026-06-24 | Urist MarshallOfficer | 9K | $502K | 0.002% | 2026-06-24 | Merrill Lynch |
| 2026-05-20 | Urist MarshallOfficer | 14K | $722K | 0.003% | 2026-05-20 | Merrill Lynch |
| 2026-05-14 | Urist MarshallOfficer | 14K | $726K | 0.003% | 2026-05-14 | Merrill Lynch |
| 2026-05-14 | Norden GregoryOfficer | 3K | $161K | 0.001% | 2026-05-14 | Merrill Lynch |
| 2025-12-16 | Sandy Lamm LLCOfficer | 160K | $6.1M | 0.037% | 2025-12-16 | Merrill Lynch |
| 2025-12-01 | Urist MarshallOfficer | 36K | $1.5M | 0.009% | 2025-12-01 | Merrill Lynch |
| 2025-12-01 | Sandy Lamm LLCOfficer | 47K | $930K | 0.011% | 2025-12-01 | Merrill Lynch |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON6 holders report 5% or more of RPRX in their latest filing, 3 on Schedule 13D (active intent). The largest reported stake is Legorreta G. Pablo at 18.7% of the class (101,785,843 shares), filed 2026-08-17 for an event on 2026-08-13.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-17 | 13D/Ano. 1 | Legorreta G. Pabloindividual | 101.8M | 18.7% | 2026-08-13 |
| 2026-08-17 | 13D/Ano. 1 | Legorreta Investments, LLCother entity | 37.5M | 7.8% | 2026-08-13 |
| 2026-06-16 | 13D/Ano. 8 | Butterfield Fiduciary Administrators Trust Company Limitedcorporation | 21.4M | 4.8% | 2026-06-12 |
| 2026-06-16 | 13D/Ano. 8 | Severgnini Achille G.individual | 21.4M | 4.8% | 2026-06-12 |
| 2026-05-14 | 13G/Ano. 3 | Capital International Investorsinvestment adviser | 37.8M | 8.8% | 2026-03-31 |
| 2026-02-20 | 13D/Ano. 7 | R & H Trust Co. (Guernsey) Limitedcorporation | 24.2M | 5.7% | 2025-11-06 |
| 2025-11-05 | 13G/Ano. 6 | FMR LLCparent holding company | 27.9M | 6.5% | 2025-09-30 |
| 2025-11-05 | 13G/Ano. 6 | Abigail P. Johnsonindividual | 27.9M | 6.5% | 2025-09-30 |
| 2025-10-30 | 13G/Ano. 3 | The Vanguard Groupinvestment adviser | 10.9M | 2.5% | 2025-09-30 |
13F holders
Tracked managers holding RPRX at their latest 13F. JSON8 of the 30 tracked managers held RPRX at their latest 13F, $638.0M in total at quarter-end prices. AQR Capital Management is the largest at $241.4M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| AQR Capital Management | 2026-06-30 | 4.3M | $241.4M | 0.08% | +523K |
| Two Sigma Investments | 2026-06-30 | 2.9M | $163.7M | 0.12% | +669K |
| Renaissance Technologies | 2026-06-30 | 1.9M | $108.5M | 0.15% | +1.1M |
| Citadel Advisors | 2026-06-30 | 1.4M | $76.0M | 0.01% | -1.3M |
| D. E. Shaw & Co. | 2026-06-30 | 525K | $29.4M | 0.01% | -597K |
| Bridgewater Associates | 2026-06-30 | 220K | $12.3M | 0.05% | new |
| Point72 Asset Management | 2026-06-30 | 107K | $6.0M | 0.01% | -383K |
| Millennium Management | 2026-06-30 | 12K | $675K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Royalty Pharma reported revenue of $674.1M, up 16.5% from the same quarter a year earlier, and net income of $17.9M (0.04 diluted EPS). In FY 2025 it generated $2.49B of operating cash flow and spent $1.23B on buybacks. As of 2026-06-30, cash was $812.0M against $8.96B of debt.
- Cash
- $812.0M
- Debt
- $8.96B
- Total assets
- $19.82B
- Shares outstanding
- 388,132,400
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $674.1M | $17.9M | 2.7% | 0.04 |
| Q1 FY 2026 | 2026-03-31 | $630.6M | $294.7M | 46.7% | 0.67 |
| Q4 FY 2025derived | 2025-12-31 | $622.0M | $211.2M | 34.0% | n/a |
| Q3 FY 2025 | 2025-09-30 | $609.3M | $288.2M | 47.3% | 0.67 |
| Q2 FY 2025 | 2025-06-30 | $578.7M | $32.2M | 5.6% | 0.07 |
| Q1 FY 2025 | 2025-03-31 | $568.2M | $239.3M | 42.1% | 0.55 |
| Q4 FY 2024derived | 2024-12-31 | $593.6M | $208.2M | 35.1% | n/a |
| Q3 FY 2024 | 2024-09-30 | $564.7M | $544.0M | 96.3% | 1.21 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $2.38B | $770.9M | $2.49B | n/a | $1.23B | n/a |
| FY 2024 | 2024-12-31 | $2.26B | $859.0M | $2.77B | n/a | $229.7M | n/a |
| FY 2023 | 2023-12-31 | $2.35B | $1.13B | $2.99B | n/a | $304.8M | n/a |
| FY 2022 | 2022-12-31 | $2.24B | $42.8M | $2.14B | n/a | $0 | n/a |
| FY 2021 | 2021-12-31 | $2.29B | $619.7M | $2.02B | n/a | $0 | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2020-11-10 from the cover page.
What this page is
Royalty Pharma in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Royalty Pharma (RPRX), SEC CIK 1802768, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-09.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-03.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-05.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-17.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-05.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-05.JSON and CSV
- Company record
- EDGAR filing index for CIK 1802768Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
- UTHRUnited Therapeutics
- CPIXCumberland Pharmaceuticals
- REGNRegeneron Pharmaceuticals
- LLYEli Lilly
- VRTXVertex Pharmaceuticals
- ALNYAlnylam Pharmaceuticals
- CYTKCytokinetics
- BMYBristol Myers Squibb
- PTCTPTC Therapeutics
- INSMInsmed
- MDGLMadrigal Pharmaceuticals
- CORTCorcept Therapeutics
- IONSIonis Pharmaceuticals
- SDGRSchrodinger
- ROIVRoivant Sciences
- JNJJohnson & Johnson
- OPKOpko Health
- ALKSAlkermes
- ABBVAbbVie
- ABTAbbott Laboratories
- KNSAKiniksa Pharmaceuticals International
- BBIOBridgeBio Pharma
- ZTSZoetis
- JAZZJazz Pharmaceuticals
Datasets
Frequently Asked Questions
How much of RPRX is sold short?
What is RPRX's daily short volume?
Does RPRX have fails to deliver?
Are RPRX insiders buying or selling?
Have RPRX insiders filed to sell?
Who owns 5% or more of RPRX?
What did RPRX report last quarter?
Which tracked 13F managers own RPRX?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.